雄激素剥夺治疗与前列腺癌患者血栓栓塞事件的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项回顾性人群队列研究,涉及170851例ADT使用者与256704例非ADT使用者,评估ADT与血栓栓塞事件的风险。结果显示GnRH激动剂单用、GnRH激动剂联合口服抗雄激素及抗雄激素单用均显著增加深静脉血栓风险,GnRH激动剂单用和睾丸切除术增加肺栓塞风险。
要点
- GnRH激动剂单用、联用口服抗雄激素或抗雄激素单用均显著增加深静脉血栓风险。
- GnRH激动剂单用和睾丸切除术显著增加肺栓塞风险。
- 睾丸切除术与深静脉血栓的关联未达统计学显著性。
核心结论
- GnRH激动剂单用、GnRH激动剂联合口服抗雄激素及抗雄激素单用均导致前列腺癌患者深静脉血栓风险增加。
- GnRH激动剂单用和睾丸切除术可增加肺栓塞发生率。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase和Cochrane Library数据库至2018年1月。
- 纳入5项回顾性人群队列研究,共170851例ADT使用者和256704例非ADT使用者。
主要发现
- 深静脉血栓与GnRH激动剂单用显著相关(HR=1.47,95%CI:1.07-2.03;P=0.017;I2=96.3%)。
- 深静脉血栓与GnRH激动剂联合口服抗雄激素显著相关(HR=2.55,95%CI:2.21-2.94;P<0.001;I2=0.0%)。
- 深静脉血栓与抗雄激素单用显著相关(HR=1.49,95%CI:1.13-1.96;P=0.004;I2=0.0%)。
- 深静脉血栓与睾丸切除术无显著关联(HR=1.80,95%CI:0.93-3.47;P=0.079;I2=94.8%)。
- 肺栓塞与GnRH激动剂单用显著相关(HR=2.26,95%CI:1.78-2.86;P<0.001;I2不可用)。
关键数值与推荐
- 深静脉血栓风险:GnRH激动剂单用HR=1.47,GnRH激动剂联合口服抗雄激素HR=2.55,抗雄激素单用HR=1.49。
- 肺栓塞风险:GnRH激动剂单用HR=2.26,睾丸切除术HR=2.12(95%CI:1.44-3.11;P<0.001;I2=57.2%)。
临床怎么用
- 对接受GnRH激动剂或抗雄激素治疗的前列腺癌患者,应评估血栓栓塞风险并考虑预防措施。
局限性
- 纳入研究均为回顾性队列研究,可能存在残余混杂。
- 部分分析异质性高(如GnRH激动剂单用与深静脉血栓的I2=96.3%)。
- 肺栓塞与GnRH激动剂单用的I2不可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether androgen deprivation therapy (ADT) causes excess thromboembolic events (TEs) in men with prostate cancer (PCa) remains controversial and is the subject of the US Food and Drug Administration safety warning. This study aims to perform a systematic review and meta-analysis on previous studies to determine whether ADT is associated with TEs in men with PCa. METHODS: Medline, Embase, and Cochrane Library databases were searched for relevant studies. These studies comprised those that compared ADT versus control to treat PCa, reported TEs as outcome, and were published before January 2018. Multivariate adjusted hazard ratios (HRs) and associated 95% confidence intervals (CIs) were calculated using random- or fixed-effects models. RESULTS: Five retrospective population-based cohort studies involving 170,851 ADT users and 256,704 non-ADT users were identified. Deep venous thrombosis (DVT) was found significantly associated with gonadotropin-releasing hormone (GnRH) agonists alone (HR = 1.47, 95% CI: 1.07-2.03; P = 0.017; I2 = 96.3%), GnRH agonists plus oral antiandrogen (AA) (HR = 2.55, 95% CI: 2.21-2.94; P < 0.001; I2 = 0.0%), and AA alone (HR = 1.49, 95% CI: 1.13-1.96; P = 0.004; I2 = 0.0%), but not with orchiectomy (HR = 1.80, 95% CI: 0.93-3.47; P = 0.079; I2 = 94.8%). In addition, pulmonary embolism (PE) was significantly associated with GnRH agonists alone (HR = 2.26, 95% CI: 1.78-2.86; P < 0.001; I2 was unavailable) and orchiectomy (HR = 2.12, 95% CI: 1.44-3.11; P < 0.001; I2 = 57.2%). This relationship was also supported with subgroup analyses based on different continents and races. CONCLUSIONS: GnRH agonists alone, GnRH plus AA, and AA alone cause excess DVT in men with PCa after controlling the demographic and disease characteristics and other confounding factors, although statistically significant difference was not observed in orchiectomy group. Additionally, GnRH agonists alone and orchiectomy can increase the incidence of PE.
引用
- Guo Z, Huang Y, Gong L, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018. PMID: 29988099. doi:10.1038/s41391-018-0059-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。